CIP-Fenofibrate for Cholesterol Disorders
Final approval has been granted for CIP-Fenofibrate (Lipofen, Cipher Pharmaceuticals), a novel formulation of the active ingredient fenofibrate, which is used in the treatment of hyperlipidemia.
Three dosages were approved: 50, 100 and 150 mg. The 150-mg strength is equivalent to Abbott’s Tricor 160 mg (under fed, not fasting, conditions). The new agent’s absorption is increased under high-fat conditions (in relation to low-fat conditions).
CIP-Fenofibrate may be used as an adjunctive therapy to diet to reduce levels of low-density lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B. It is also indicated for raising high-density lipoprotein cholesterol levels in adults with primary hyper-cholesterolemia or mixed dyslipidemia and in adults with hypertriglyceridemia.
CIP-Fenofibrate tablet is based on the Lidose delivery system (consisting of oral semi-liquid capsules).
